Researchers Studying Oral Medication to See if it Protects the Brain During Radiation Therapy Treatment for Primary Central Nervous System Tumors
Phase: Recruiting
First Posted: March
Condition(s): Central Nervous System (CNS) Tumors
NCT Number: NCT04939597 Other Study ID Number(s): ACCL2031
What Is the Purpose of This Study?
To see if oral medication memantine protects the brain during radiation therapy treatment for primary central nervous system tumors.
Who Can Take Part in This Study?
People who may be eligible for this study:
- Primary central nervous system tumors that have not received prior cranial radiotherapy.
- Are 4-17 years old.
For a full list of eligibility requirements, visit https://clinicaltrials.gov/study/NCT04939597
What Will Happen During This Study?
Patients randomized to receive oral medication memantine or placebo daily for 24 weeks. Patients also complete cognitive function testing and quality of life (QOL) surveys at baseline, end of radiation therapy, and at 3, 6, 12, 24, and 48 months. Patients may optionally undergo blood sample collection throughout the trial.